Prostate enlargement, which is called Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement and is common in ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, ...

TD Cowen 46th Annual Health Care Conference March 2, 2026 11:50 AM ESTCompany ParticipantsLarry Wood - President, ...

Clinically known as benign prostatic hyperplasia (BPH), enlarged prostate is a non‑cancerous condition that affects roughly half of men ages 51 to 60, with incidence increasing ...

Our kidneys are remarkable organs, silently working 24/7 to filter waste, regulate blood pressure, and produce essential hormones. Often, we don’t think about them until something goes wrong.

The FDA granted the approval following findings from the pivotal POETYK PsA-I and POETYK PsA-II Phase III studies.

Profound Medical (NASDAQ:PROF) reported fourth-quarter 2025 revenue of $6.0 million, including $2.3 million in recurring ...

CEO Jim Clemmer said the company has spent the last several years reshaping its portfolio and operating model, moving away ...

KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.

Prostate Enlargement Treatment: Prostate problems are increasing rapidly in men. Let us tell you which major signs should not be ignored after 40 and when should you consult a doctor? What are the ...

The EAU 2026 CAPTAIN study presentation will be given by Laurence Klotz, CM, MD, FRCSC, an esteemed urologist, a professor of surgery at the University of Toronto, the Sunnybrook Chair of Prostate ...

Urologists at Vanderbilt Health are enrolling men with stress urinary incontinence (SUI) in a clinical trial named SOPHIA2 to assess the safety and efficacy of the UroActive implant, following an ...